Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy
- 25 October 2005
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 44 (1), 151-157
- https://doi.org/10.1016/j.jhep.2005.09.010
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Mcl-1 Is a Novel Therapeutic Target for Human SarcomaClinical Cancer Research, 2004
- Antisense therapy for cancer—the time of truthThe Lancet Oncology, 2002
- Expression of Mcl‐1 in mantle cell lymphoma is associated with high‐grade morphology, a high proliferative state, and p53 overexpressionThe Journal of Pathology, 2002
- Bcl-XL is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapyInternational Journal of Cancer, 2002
- Apoptosis-based therapiesNature Reviews Drug Discovery, 2002
- Distinct roles for extracellular-signal-regulated protein kinase (ERK) mitogen-activated protein kinases and phosphatidylinositol 3-kinase in the regulation of Mcl-1 synthesisBiochemical Journal, 2001
- Regulation of Apoptosis and Cell Cycle Progression by MCL1Journal of Biological Chemistry, 2000
- In vivo localisation and stability of human Mcl‐1 using green fluorescent protein (GFP) fusion proteinsFEBS Letters, 2000
- Antiapoptotic Action of 1,25-Dihydroxyvitamin D3Is Associated with Increased Mitochondrial MCL-1 and RAF-1 Proteins and Reduced Release of Cytochrome cExperimental Cell Research, 1997
- The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2.The Journal of cell biology, 1995